Morningside
Morningside is a venture capital firm based in the greater Boston area, specializing in investments in companies that focus on innovative science and technology. Established in 1986 as a family office for the Chan family, Morningside emphasizes a long-term approach to company-building and maintains a strong commitment to ethical practices. The firm is staffed by a team of experienced investment professionals with expertise in various sectors, including life sciences, digital health, artificial intelligence, materials, and technology. In addition to its investment activities, Morningside is dedicated to philanthropic efforts, supporting education, research, and healthcare initiatives such as the Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and the MIT Morningside Academy for Design.
Top Stages
Past deals in Boston, MA
Almond FinTech
Seed Round in 2021
Almond FinTech is a blockchain-based cross-border payments platform that connects a global network of financial institutions to enable individuals and businesses to send money across borders using existing wallets and bank accounts. It provides the technology and network to support peer-to-peer transfers, digital currency-based international settlements, and near-instant settlements across corridors worldwide. The platform offers APIs for currency exchange interoperability between mobile wallets and services, along with a white-labeled web or mobile interface for partners. With a focus on speed, security, and accessibility, Almond FinTech aims to streamline remittances and cross-border payments by leveraging a shared transfer network built on blockchain-enabled infrastructure.
Catalant
Venture Round in 2021
Catalant is a Boston-based software company that specializes in strategy execution solutions for global enterprises. Founded in 2013, the company's platform enables businesses to break down strategic objectives, access and deploy resources, collaborate, measure value, and improve processes. Catalant's network comprises over 65,000 experts and 1,000 firms, serving more than 30% of the Fortune 100. Additionally, Catalant offers a platform that connects private equity firms with business professionals.
Prilenia
Series A in 2020
Prilenia is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative and neurodevelopmental disorders. Founded in 2018 and operating from locations in Israel, the Netherlands, and Boston, the company’s primary asset is Pridopidine, an oral drug candidate noted for its established safety profile. Pridopidine demonstrates potential in treating various movement disorders and neurodegenerative diseases that affect both adults and children, aiming to help healthcare institutions preserve functional capacity in patients, including those undergoing early hemodialysis.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.